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Abstract
Background: Probability of recurrence in patients with estrogen receptor (ER)-positive breast cancer remains constant for
long periods. We compared tumor burden impact on late versus early recurrence in our cohort with long-term follow-up.
Methods: Five hundred and ninety five patients diagnosed with ER-positive breast cancer between 1989 and 2001 were
classified into three groups: early recurrence within 5 years, late recurrence after 5 years, and no recurrence. We identified
prognostic factors among the groups using logistic regression analysis.
Results: At median follow-up of 11.7 years, among 595 ER-positive women, 98 (16.4%) had early recurrence and 58 (9.7%)
had late recurrence. On multivariate analysis, higher nodal stage (N0 vs. N2, odds ratio [OR] 3.189; N0 vs. N3, OR 9.948),
higher histologic grade (grade 1 vs. grade 2, OR 3.896; grade 1 vs. grade 3, OR 5.945), age .35 years (OR 0.295), and
receiving endocrine therapy (OR 0.293) affected early recurrence. Compared to no recurrence, receiving endocrine therapy
(OR 0.285) was solely related to decreased risk of late recurrence. Increased risk of early recurrence was noted with the
higher nodal stage when early and no recurrences were compared. This phenomenon was not found in late recurrence. In
the last comparison between the early and late recurrence, higher nodal stage (N0 vs. N3, OR 16.779) and higher histologic
grade (grade 1 vs. grade 3, OR 18.111) repeatedly weighted for early recurrence.
Conclusions: Nodal burden had an attenuated influence on late recurrence, which suggests that, unlike early recurrence,
tumor biology might have a more important role than tumor load for late recurrence in ER-positive disease.
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Introduction
Breast cancer is the most common cancer in women, with
approximately 1.5 million new cases diagnosed annually world-
wide, a lifetime risk of up to 12%, and a risk of death of up to 5%
in Western countries [1]. With advances in early detection and
improvements in breast cancer treatment, markedly increasing
long-term survivors who remain at risk of recurrence are raising
issues for oncologists [2–4]. Therefore, the identification of factors
influencing late recurrence after 5 years has become increasingly
important.
Previous studies reported that the risk of early relapse is greater
for women with estrogen receptor (ER)-negative than ER-positive
breast cancer, but late relapses are more common in ER-positive
than ER-negative disease [4–6]. Although the use of endocrine
therapy in clinical practice remarkably enhanced survival
outcomes of ER-positive patients [7], the probability of recurrence
among patients with ER-positive disease remains constant over
time [4–6]. In this context, recent studies have focused on the
residual risk of late recurrence among long-term survivors with
ER-positive disease [8,9].
Tumor size and number of involved lymph nodes representing
tumor burden are the most important prognostic factors for breast
cancer recurrence [10,11]. Tumor relapse in the early period
following treatment has conventionally been considered a problem
of excess tumor burden regardless of ER status. Previous studies
reported that nodal stage was associated with early recurrence
within 5 years in ER-positive breast cancer [12,13], and this
conventional concept was also confirmed in patients with ER-
negative disease. With respect to late recurrence after 5 years,
several studies demonstrated that advanced stage of the primary
tumor raised the risk of late relapse [11,14,15], but these studies
also included ER-negative breast cancer patients.
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With this landscape, we hypothesized that tumor load,
recognized as an important prognostic factor for early recurrence,
might influence late recurrence differently in ER-positive disease.
In this study, we investigated the prognostic factors of early
recurrence within 5 years and late recurrence after 5 years in ER-
positive breast cancer patients.
Patients and Methods
Patients
The institutional review board (IRB) of Gangnam Severance
Hospital, Yonsei University, Seoul, Korea, approved the study in
accordance with good clinical practice guidelines and the
Declaration of Helsinki (local IRB approval number: 2012-
0199). The need for informed consent was waived because of
the retrospective design. Patients included in this study were
retrospectively selected from the database of breast cancer patients
treated between January 1991 and December 2001 at Gangnam
Severance Hospital, Yonsei University Medical College, Seoul,
Korea. During the period, 1,329 patients were treated for breast
cancer and entered into the database. The follow-up protocol
included planned regular visits every six months and requests for
missed appointments with telephone calls were made to minimize
patient loss and raise the accuracy of survival data. The last update
of the clinical database was in April 2012. Among 1106 patients
with known ER status, 677 had ER-positive breast cancer. Patients
with ductal carcinoma in situ, distant metastases at initial
assessment, and clinical or pathological stage T4 disease were
excluded. Those who received preoperative chemotherapy were
eliminated from this study because of inaccurate assessment for
clinical tumor staging. Patients with unavailable information of
tumor characteristics and endocrine therapy were also excluded
from these analyses. Contralateral breast cancer was not defined as
recurrence because it could not be determined whether the disease
was true recurrence or new primary. Similarly, ipsilateral breast
tumor recurrence following breast-conserving surgery could not be
determined as recurrence because there was a lack of pathological
information. As a result, the patients with metachronous
contralateral breast cancer and ipsilateral breast tumor recurrence
were excluded.
Following the exclusion, we retrieved data from 595 consecutive
patients with ER-positive breast cancer who underwent curative
surgery. Before February 1999, ER status was determined by the
ligand binding assay, and tumors were considered ER-positive if
they scored.10 fmol/mg [16]. From February 1999, the
immunohistochemical (IHC) method for ER staining was intro-
duced and replaced the biochemical method. T and N stage were
classified according to the American Joint Committee on Cancer
(AJCC), 6th edition. The modified Scarf-Bloom-Richardson
grading system was used for tumor grading.
The site of recurrence was classified as local (ipsilateral breast or
chest wall), regional (ipsilateral axillary, infraclavicular, internal
mammary, or supraclavicular), or distant metastasis (any other
site). Early recurrence was defined as initial recurrence within 5
years following curative surgery irrespective of site. Likewise, late
recurrence was defined as initial recurrence after 5 years.
According to the timing of first the recurrence, all patients were
stratified into three groups (early recurrence, late recurrence, and
no recurrence during the follow-up period). Receiving endocrine
therapy was defined as a patient who completed a 5-year course of
endocrine therapy. The patients underwent recurrence during the
period of endocrine therapy were also classified as the group of
endocrine treatment. Patients receiving endocrine therapy after
first relapse were excluded from the group treated with endocrine
agents. Patients receiving adjuvant radiation therapy, which affects
recurrence rates, were also investigated.
Statistics
The Chi-square test was used to compare baseline tumor
characteristics. The primary end-point was recurrence-free
survival defined as the interval from curative surgery to the first
recurrence of breast cancer irrespective of the site. The binary
logistic regression models were employed to compare character-
istics between the no recurrence and early or late recurrence
groups. The significant prognostic factors associated with early or
late recurrence were selected according to the Akaike Information
Criterion in a stepwise fashion while avoiding over-parameteriza-
tion.
The secondary end-point was distant metastasis-free survival
that has a major impact on overall survival. Multivariate
comparison was used to identify prognostic factors significantly
associated with early or late metastasis. The number of recurrence
sites was greater than the number of patients with recurrence
because of the patients with multiple recurrent sites including both
loco-regional recurrence and distant metastasis.
For examination a trend between recurrence groups and nodal
stage, linear-by-linear association chi-squared test was performed.
All statistical analyses were performed using the SPSS statistics
program version 18.0 (SPSS Inc., Chicago, IL) and R (http://
www.r-project.org) software. A p-value,0.05 was considered
statistically significant.
Results
Recurrence Pattern
In 595 ER-positive patients, the median age at diagnosis of
primary tumor was 45 years (range, 23 to 80). At a median follow-
up of 11.7 years (range, 0.3 to 20.4), 156 recurrences occurred,
with 98 early recurrences and 58 late recurrences reported. There
were 91 early and 58 late distant metastasis reported, leaving seven
patients who had sole loco-regional recurrence without distant
metastasis. According to the site of recurrence, there were 26 local,
seven regional, and 149 distant recurrences. During the follow-up
period, 119 deaths occurred.
Surgical, Endocrine, and Radiation Treatments
There were 393 (66.1%) patients who underwent mastectomy
and 202 (33.9%) received breast-conserving surgery. Among 502
patients receiving endocrine treatment, 275 women were treated
with tamoxifen, 192 with toremifen, and one with letrozole.
Eighteen patients switched from tamoxifen to toremifen or
toremifen to tamoxifen and 16 had extension with letrozole after
completing 5 years of tamoxifen treatment. Among the patients
receiving endocrine therapy, 107 had a recurrence with 67
occurring during the treatment period. Of these, 48 continued the
treatment or changed endocrine agents while 19 stopped
endocrine therapy. Forty patients had a recurrence after
completing 5 years of treatment.
263 patients received adjuvant radiation therapy (44.2%). In
202 patients with breast conservation surgery, radiation therapy
was performed for 190 patients (94.1%). Among 393 patients with
mastectomy, 73 women received adjuvant radiotherapy (18.6%).
Patient Characteristics
Baseline tumor characteristics are listed and compared in the
paired groups (Table 1). Compared with the late recurrence
group, the early recurrence group tended to have a younger age,
and higher nodal stage and histologic grade. A similar trend was
Prognostic Factors for Early and Late Recurrence
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found that women in the early recurrence group had a younger
age, larger tumor size, higher nodal stage, higher histologic grade,
more lymphovascular invasion, and received endocrine therapy
with a lower frequency compared to the no recurrence group.
Compared with women without recurrence, women with late
recurrence had larger tumor size and higher nodal stage.
Moreover, the patients not receiving endocrine therapy tended
to have more frequent late recurrence than the patients who
received endocrine therapy.
Regarding the rates of radiation therapy, there was no
difference according to recurrence status. In this study, radiation
treatment did not affect the pattern of recurrence in ER-positive
patients.
Prognostic Factors using Binary Logistic Regression
Model
In comparison to no recurrence, age under 35 years (odds ratio
[OR] 0.295, 95% CI 0.120–0.730), higher nodal stage (N0 to N2,
OR 3.189, 95% CI 1.210–8.410; N0 to N3, OR 9.948, 95% CI
3.828–25.853), higher histologic grade (grade 1 to grade 2, OR
3.896, 95% CI 1.365–11.124; grade 1 to grade 3, OR 5.945, 95%
CI 1.892–18.685), and receipt of endocrine therapy (OR 0.293,
95% CI 0.130–0.659) were significant prognostic factors for early
recurrence within 5 years (Table 2). With respect to no metastasis,
higher nodal stage (N0 to N3, OR 11.349, 95% CI 4.166–30.922),
higher histologic grade (grade 1 to grade 2, OR 3.285, 95% CI
1.140–9.464; grade 1 to grade 3, OR 4.503, 95% CI 1.409–
14.395), and receipt of endocrine therapy (OR 0.198, 95% CI
0.087–0.453) were significantly associated with an early metastasis
within 5 years compared to no metastasis (Table 2). In both
Table 1. Patient characteristics according to recurrence pattern.
No. patients x2 test
Characteristics
Early recurrence
within 5 years:
Group 1 (n =98)
Late recurrence
after 5 years:
Group 2 (n=58)
No recurrence:
Group 3 (n =439)
Group 1 vs.
Group 2
Group 2 vs.
Group 3
Group 3 vs.
Group 1
Age 0.022 0.410 ,0.001
Age,35 (n = 63) 25 6 32
Age$35 (n = 532) 73 52 407
Tumor size 0.848 0.006 ,0.001
$2 cm (n = 236) 74 15 197
,2 cm (n = 359) 24 43 242
N stage 0.014 0.001 ,0.001
N0 (n = 325) 28 21 276
N 1 (n = 172) 26 24 122
N2 (n = 55) 18 9 28
N3 (n = 43) 26 4 13
Histologic gradea 0.002 0.101 ,0.001
1 (n = 163) 13 19 131
2 (n = 249) 50 32 167
3 (n = 77) 21 3 53
Progesterone receptora 0.541 0.430 0.053
Presence (n = 463) 73 48 342
Absence (n = 74) 18 9 47
Lymphovascular invasiona 0.267 0.083 ,0.001
Presence (n = 33) 13 4 16
Absence (n = 412) 52 36 324
Endocrine therapy 0.938 ,0.001 ,0.001
Yes (n = 502) 67 40 395
No (n = 93) 31 18 44
Surgical method 0.582 0.702 0.203
Mastectomy (n = 393) 70 39 284
BCS (n = 202) 28 19 155
Radiotherapy 0.945 0.674 0.433
Yes (n = 263) 40 24 199
No (n = 332) 58 34 240
Abbreviation: BCS, breast-conserving surgery.
aValues with missing data.
doi:10.1371/journal.pone.0063510.t001
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comparisons, higher nodal stage was significantly associated with
an increased risk of early recurrence or metastasis.
Next, comparison of late recurrence after 5 years and no
recurrence suggested that only receipt of endocrine therapy (OR
0.285, 95% CI 0.115–0.704) was related with a decreased risk of
late recurrence after 5 years (Table 3). Receipt of endocrine
therapy also remained a significant prognostic factor (OR 0.265,
95% CI 0.105–0.666) for metastasis after 5 years compared to no
metastasis (Table 3). The negative impact of nodal stage on early
recurrence observed in the comparison above was not found in
this analysis.
These analyses identified different prognostic factors for early
and late recurrence. In the next step, we directly compared the
prognostic factors between early and late recurrence. In the
analysis, higher nodal stage (N0 to N3, OR 16.799, 95% CI
1.848–152.353) and higher histologic grade (grade 1 to grade 3,
OR 18.111, 95% CI 2.644–124.085) remained as significant risk
factors for early recurrence within 5 years (Fig. 1). Comparing
early and late metastasis, these two characteristics repeatedly
weighted for early metastasis within 5 years (N0 to N3, OR
16.570, 95% CI 1.798–152.670; grade 1 to grade 3, OR 10.783,
95% CI 1.818–63.967; Fig. 1).
The goodness of fit for the binary logistic models employed in
this study was investigated using the Hosmer and Lemeshow test
and receiver operating characteristic curves. As summarized in
Figs. S1, S2, S3, S4, S5, and S6 and Table S1, the goodness of fit
tests supported all multivariate comparison models with P-values
greater than 0.069 and are under the curve values ranged from
0.70 to 0.83.
Impact of Nodal Stage on Recurrence
We conducted additional investigations to obtain further insight
regarding the relationship of nodal stage and recurrence (Fig. 2).
In the figure, each histogram indicates the proportion of patients
with the recurrence groups in each nodal stage. The proportion of
patients with early recurrence was increased in higher nodal stage;
however, an inverse trend was observed in the relationship of no
recurrence and higher nodal stage. In the pattern with late
recurrence, linear trend based on nodal stage was not found.
Annual recurrence rates by nodal stage during the first 10 years
are illustrated in Fig. 3. Overall recurrence ranged from 1.3 to
3.8% and it was 2.6% in the ninth year. The highest recurrence
rate was 23.3% in the first year in patients with N3 disease, and it
remained high over the first 5 years, then decreased gradually
thereafter. Women with N2 stage disease showed a relatively high
recurrence rate during years 2 to 4, and the rate slightly decreased
after 5 years. The patients with N0 and N1 generally showed low
recurrence rate during 10 years (N1, 0.3 to 5.0%; N0, 0.5 to
2.3%).
Discussion
In a cohort study of ER-positive breast cancer patients with
long-term follow-up, the well-known phenomenon of late recur-
rence was observed in our data. The overall recurrence rate after 5
years persisted constantly (range, 1.3 to 2.6%; Fig. 3). In the
comparisons of characteristics among the groups, early recurrence
or metastasis group showed remarkable features related to
aggressive tumor behavior, such as young age, large tumor size,
higher nodal stage, and higher histologic grade (Table 2). The
Table 2. Binary logistic regression analysis comparing recurrence or metastasis within 5 years of diagnosis with no recurrence or
no metastasis.
Any type of recurrence Distant metastasis
Characteristics No. patients OR (95% CI) P value No. of patients OR (95% CI) P value
Age 0.008 n/ab n/ab n/ab
Age,35 31 Reference
Age.=35 315 0.295 (0.120–0.730)
Tumor size n/ab n/ab n/ab 0.149
$2 cm 141 Reference
,2 cm 204 1.852 (0.803–4.273)
N stage ,0.001 ,0.001
N0 178 Reference 179 Reference
N1 107 1.595 (0.719–3.537) 0.250 106 1.513 (0.654–3.504) 0.333
N2 32 3.189 (1.210–8.410) 0.019 31 2.573 (0.898–7.388) 0.078
N3 29 9.948 (3.828–25.853) ,0.001 29 11.349 (4.166–30.922) ,0.001
Histologic gradea 0.009 0.036
1 108 Reference 108 Reference
2 176 3.896 (1.365–11.124) 0.011 176 3.285 (1.140–9.464) 0.028
3 62 5.945 (1.892–18.685) 0.002 61 4.503 (1.409–14.395) 0.011
Endocrine therapy 0.003 ,0.001
No 39 Reference 38 Reference
Yes 307 0.293 (0.130–0.659) 307 0.198 (0.087–0.453)
Abbreviation: n/a, not applicable.
aValues with missing data.
bA binary logistic regression model was selected using Akaike Information Criteria (AIC) in stepwise selection. Odds ratios are adjusted for all of the factors listed in the
table.
doi:10.1371/journal.pone.0063510.t002
Prognostic Factors for Early and Late Recurrence
PLOS ONE | www.plosone.org 4 May 2013 | Volume 8 | Issue 5 | e63510
Table 3. Binary logistic regression analysis comparing recurrence or metastasis after 5 years of diagnosis with no recurrence or no
metastasis.
Any type of recurrence Distant metastasis
Characteristics No. patients OR (95% CI) P value No. of patients OR (95% CI) P value
Tumor size n/ab n/ab n/ab 0.156
$2 cm 141 Reference
,2 cm 188 1.803 (0.798–4.073)
N stage 0.078 0.074
N0 175 Reference 176 Reference
N1 112 2.693 (1.256–5.773) 0.011 112 2.817 (1.251–6.344) 0.012
N2 26 2.298 (0.656–8.055) 0.194 28 2.769 (0.819–9.368) 0.101
N3 13 1.265 (0.147–10.926) 0.831 13 1.177 (0.133–10.427) 0.883
Histologic gradea 0.064 0.122
1 113 Reference 112 Reference
2 167 1.837 (0.824–4.096) 0.136 170 1.766 (0.758–4.112) 0.187
3 46 0.388 (0.078–1.932) 0.248 47 0.552 (0.134–2.275) 0.411
Endocrine therapy 0.007 0.005
No 32 Reference 31 Reference
Yes 294 0.285 (0.115–0.704) 298 0.265 (0.105–0.666)
Abbreviation: n/a, not applicable.
aValues with missing data.
bA binary logistic regression model was selected using AIC in stepwise selection. Odds ratios are adjusted for all of the factors listed in the table.
doi:10.1371/journal.pone.0063510.t003
Figure 1. Illustrated odds ratio in the comparison between early recurrence or metastasis within 5 years and late recurrence or
metastasis after 5 years. A binary logistic regression model was selected using Akaike Information Criteria in stepwise selection. Odds ratios are
adjusted for all of the factors illustrated in the figure.
doi:10.1371/journal.pone.0063510.g001
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observation that women with these characteristics have a high risk
of early recurrence was reported in multiple earlier studies [12,13].
In contrast, women with late recurrence did not seem to have
aggressive tumor characteristics compared with women without
recurrence (Table 3). Among tumor characteristics reflecting
tumor load, only nodal stage was demonstrated as a prognostic
factor associated with early recurrence. Tumor size reported as an
important prognostic factor for recurrence in the previous studies
was not significantly demonstrated in this study [10–13].
In this investigation, we found a different prognostic impact of
nodal stage between early and late recurrence in ER-positive
women. For early recurrence within 5 years, higher nodal stage
linearly increased the hazard of recurrence (N0 to N1, OR 1.595;
N0 to N2, OR 3.189; N0 to N3, OR 9.948; Table 2). This linear
correlation was not found in the relationship of late recurrence and
nodal stage. Of course, women with N1 disease had an OR of
2.693 compared with women with N0 (P= 0.011); however, the
increasing hazard for late recurrence according to higher nodal
stage was not observed (N0 to N2, OR 2.298; N0 to N3, OR
1.265, respectively; Table 3). In the final logistic analysis, we
compared the two recurrence groups to evaluate the different
impact of prognostic factors. Higher nodal stage emerged as a
significant risk factor for early recurrence in this final analysis. This
prominently decreased effect of nodal stage was similarly observed
in the comparison of early metastasis within 5 years and late
metastasis after 5 years. The finding of diminished influence of
nodal stage on late recurrence compared with early recurrence
strongly suggests that factors related to tumor biology have a more
pivotal role than tumor load in late recurrence of ER-positive
disease. This perspective is concordant with the studies to elucidate
tumor biology contributing to late recurrence [17–19]. Towards
this goal, recent research also identified novel molecules which
participate in the process of late relapse [20–22] and the classical
hypothesis of tumor dormancy was developed to explain late
recurrence [2,11].
However, in parallel comparison between early recurrence and
late recurrence, the major impact of nodal stage should be
considered. Recently, many investigators sought to distinguish
patients who are at risk for early relapse versus late relapse in ER-
positive breast cancer using biomarkers or molecular approaches
[23–25]. These novel methods provided important information in
understanding the tumor biology associated with early and late
recurrence of ER-positive disease. However, our results suggested
that the profound influence of nodal stage on early recurrence
should not be overlooked. Prior to parallel analysis of early
recurrence and late recurrence, adjustment for the effect of nodal
stage is necessary.
In a previous study [9], Kennecke et al. already reported that T
and N stages predicted late relapse and death from estrogen
responsive early breast cancer in postmenopausal women. In
contrast to our study, the authors compared two groups stratified
by cohorts without and with late recurrence. Therefore, the
different prognostic impact of nodal stage on early vs. late
recurrence in ER-positive disease was not explored.
To suppress recurrence, endocrine therapy has been an integral
part of adjuvant treatment modalities in ER-positive patients. The
endocrine agents provided a great survival benefit for women with
ER-positive breast cancer, and selective estrogen receptor
modulators and/or aromatase inhibitors showed a significant
reduction in recurrence after treatment completion [26,27]. The
protective carryover effect of endocrine therapy was similarly
noted in this analysis. Among patients treated with tamoxifen or
toremifen, the observed therapeutic effect in the late period was
consistent with that of large studies [26,27]. However, 40 women
in this study experienced late recurrence after 5 years despite
endocrine therapy. Late recurrence despite endocrine therapy has
been a challenging obstacle to overcome.
Figure 2. Histograms of three groups based on recurrence:
early recurrence within 5 years, late recurrence after 5 years,
and no recurrence. Each histogram indicates the proportion of
patients with the recurrence groups in each nodal stage. Linear-by-
linear association chi-squared test was performed for examination a
trend between recurrence groups and nodal stage (P,0.001).
doi:10.1371/journal.pone.0063510.g002
Figure 3. Annual recurrence rate by nodal stage.
doi:10.1371/journal.pone.0063510.g003
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Retrospective design is a major limitation in this study. This
study could be affected by the bias associated with the decision of
endocrine therapy or the inherent selection bias of retrospective
studies. In addition, human epidermal receptor-2 (HER-2) status
was not evaluated in this study because the routine IHC test for
HER-2 was not done in the investigated period. Moreover, the
grade of ER positivity could not be assessed in this study. The ER
grade is reported to be related with endocrine responsiveness and
associated with survival outcome of ER-positive patients [12].
Because of the absence of information on HER-2 status and ER
grade, further studies to define biologic effect of these factors on
late recurrence still remains an unmet need. Future work with the
identification of novel biomarkers as well as HER-2 and ER grade
could support and strengthen our findings regarding early and late
recurrence in ER-positive women.
In the article, the dissimilarity in prognostic factors between
early recurrence and late recurrence in ER-positive disease was
noted. Above all, this investigation highlights the diluted effect of
nodal stage on late recurrence compared with early recurrence,
and it suggests that tumor biology plays a more important role
than tumor load in late recurrence of ER-positive disease. Our
results propose that comprehensive consideration of both tumor
load and tumor biology is needed to perform the translational
research involving parallel comparison between early and late
recurrence in this subset of patients.
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